We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In this special report, Drug Industry Daily examines the current state of clinical research on Alzheimer’s disease interventions. Part one focuses on the array of anti-amyloid candidates, the controversy surrounding some and the prospects for others.Read More
Results of a Merck/Moderna collaboration are the first evidence of efficacy for an investigational mRNA cancer treatment in a randomized clinical trial, according to the companies. Read More
Novartis announced that its radioligand chemotherapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) extended progression-free survival in men with previously treated prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Read More
A drug candidate developed by Sanofi and the Drugs for Neglected Diseases initiative (DNDi) has shown very high efficacy in treating sleeping sickness, a sometimes lethal condition that is endemic across Sub-Saharan Africa. Read More
In the wake of twin phase 3 failures, Roche will discontinue all active trials of the antiamyloid antibody gantenerumab, the company confirmed at the Clinical Trials on Alzheimer’s Disease annual meeting in San Francisco. Read More
TauRx went big at the Clinical Trials on Alzheimer’s Disease (CTAD) annual meeting in San Francisco, insisting that its investigational anti-tau agent, hydromethylthionine mesylate (HMTM), exerted cognitive benefit and slowed brain atrophy in an ongoing phase 3 trial — despite a prior admission that a blinded study of the drug is virtually impossible. Read More
Eisai’s antiamyloid antibody lecanemab nearly eliminated amyloid brain plaques in 68 percent of Alzheimer’s (AD) patients, while modestly slowing decline on all four cognitive and functional measures in the CLARITY AD study, company executives and clinicians involved in the study said at the Clinical Trials on Alzheimer’s Disease annual meeting in San Francisco. Read More
Axsome Therapeutics’ proprietary combination of dextromethorphan and bupropion — already approved for major depressive disorder as AXS-05 — also reduced the risk of agitation related to Alzheimer’s disease (AD), the company reported. Read More
Lysogene’s investigational gene therapy LYS-SAF302 preserved cognitive function and brain volume in a small set of infants with a devastating type of childhood dementia, mucopolysaccharidosis Type IIIA (MPS IIIA). Read More